The Future of Life Sciences VC: Examining Specialist vs. Hyper-Targeted Investment Strategies
Live Webinar | May 8th 2025 | 3:00 PM BST | 60 Minutes
45-minute expert panel discussion +15-minute audience Q&A
In an evolving biotech and medtech investment landscape, life sciences VCs are adopting increasingly distinct approaches. Some embrace a specialist model, investing across a broad range of technologies and therapeutic areas. Others double down with hyper-targeted strategies, focusing on a narrow field to build deep expertise and insight.
But which path is more effective for driving returns, de-risking investments, and enabling impactful innovation?
Join us for this dynamic panel debate as we explore the models shaping the next generation of life science venture capital.
What We’ll Cover:
Defining the Models:
Understand the core differences in structure, strategy, and focus between Specialist and Hyper-Targeted VCs.
What Drives the Approach:
Explore the external forces—market trends, capital cycles, LP expectations—that shape VC strategy.
Who Has the Edge?
Dive into the competitive advantages: from deal sourcing and domain insight to resilience and exit performance.
Sector Spotlights:
Identify the therapeutic and technology areas where deep specialization is driving results.
Portfolio Strategy Takeaways:
What should GPs and LPs consider when building a robust and adaptable investment thesis?